- Home
- EYPT
as 04-22-2025 4:00pm EST
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 427.9M | IPO Year: | 2005 |
| Target Price: | $25.71 | AVG Volume (30 days): | 841.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.91 - $21.26 | Next Earning Date: | 05-07-2025 |
| Revenue: | $43,273,000 | Revenue Growth: | -5.96% |
| Revenue Growth (this year): | -42.04% | Revenue Growth (next year): | -42.41% |
Latest EyePoint Pharmaceuticals Inc. News
EYPT Breaking Stock News: Dive into EYPT Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 days ago
Here's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn Situation
GlobeNewswire
a month ago
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
GlobeNewswire
a month ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Simply Wall St.
2 months ago
Despite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32k
Thomson Reuters StreetEvents
2 months ago
Q4 2024 EyePoint Pharmaceuticals Inc Earnings Call
GuruFocus.com
2 months ago
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ...
Zacks
2 months ago
EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say
Zacks
2 months ago
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates
Compare EYPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.